NCT05353205 - A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

September 30, 2025

Conditions

CML, Chronic Phase

Interventions

DRUG

Flumatinib mesylate tablets (400mg)

Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.

DRUG

Flumatinib mesylate tablets (600mg)

Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.

Trial Locations (1)

RECRUITING

Institute of Hematology and Oncology, Harbin The First Hospital, Harbin